104 related articles for article (PubMed ID: 24299208)
41. Phosphatidylinositol 3-kinase could be a promising target in lung cancer therapy.
Wang H; Wu H; Cai K; Ju Q; Wang W
J BUON; 2012; 17(4):729-34. PubMed ID: 23335533
[TBL] [Abstract][Full Text] [Related]
42. Amplifications of proto-oncogenes in ovarian carcinoma.
Bian M; Fan Q; Huang S; Ma J; Lang J
Chin Med J (Engl); 1995 Nov; 108(11):844-8. PubMed ID: 8585978
[TBL] [Abstract][Full Text] [Related]
43. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).
Jiang W; Ye S; Xiang L; Yang W; He T; Pei X; Guo L; Yang H
J Ovarian Res; 2018 Jul; 11(1):58. PubMed ID: 29986747
[TBL] [Abstract][Full Text] [Related]
44. Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
Maru Y; Tanaka N; Ohira M; Itami M; Hippo Y; Nagase H
Gynecol Oncol; 2017 Feb; 144(2):377-383. PubMed ID: 27939411
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer.
Woenckhaus J; Steger K; Sturm K; Münstedt K; Franke FE; Fenic I
Virchows Arch; 2007 Apr; 450(4):387-95. PubMed ID: 17377809
[TBL] [Abstract][Full Text] [Related]
46. A clearer view on ovarian clear cell carcinoma.
De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
[TBL] [Abstract][Full Text] [Related]
47. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.
Kuo KT; Mao TL; Chen X; Feng Y; Nakayama K; Wang Y; Glas R; Ma MJ; Kurman RJ; Shih IeM; Wang TL
Clin Cancer Res; 2010 Apr; 16(7):1997-2008. PubMed ID: 20233889
[TBL] [Abstract][Full Text] [Related]
48. Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks.
Murakami R; Matsumura N; Brown JB; Higasa K; Tsutsumi T; Kamada M; Abou-Taleb H; Hosoe Y; Kitamura S; Yamaguchi K; Abiko K; Hamanishi J; Baba T; Koshiyama M; Okuno Y; Yamada R; Matsuda F; Konishi I; Mandai M
Am J Pathol; 2017 Oct; 187(10):2246-2258. PubMed ID: 28888422
[TBL] [Abstract][Full Text] [Related]
49. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
50. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.
Arnedos M; Scott V; Job B; De La Cruz J; Commo F; Mathieu MC; Wolp-Diniz R; Richon C; Campone M; Bachelot T; Dalenc F; Dessen P; Lacroix L; Lazar V; Soria JC; Delaloge S; Andre F
Eur J Cancer; 2012 Oct; 48(15):2293-9. PubMed ID: 22840369
[TBL] [Abstract][Full Text] [Related]
51. Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
Itamochi H; Kato M; Nishimura M; Oumi N; Oishi T; Shimada M; Sato S; Naniwa J; Sato S; Nonaka M; Kudoh A; Terakawa N; Kigawa J; Harada T
Hum Cell; 2013 Sep; 26(3):121-7. PubMed ID: 23430509
[TBL] [Abstract][Full Text] [Related]
52. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract][Full Text] [Related]
53. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
Ismail SI; Mahmoud IS; Msallam MM; Sughayer MA
Leuk Res; 2010 Jun; 34(6):824-6. PubMed ID: 20022634
[TBL] [Abstract][Full Text] [Related]
54. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
Kolasa IK; Rembiszewska A; Felisiak A; Ziolkowska-Seta I; Murawska M; Moes J; Timorek A; Dansonka-Mieszkowska A; Kupryjanczyk J
Cancer Biol Ther; 2009 Jan; 8(1):21-6. PubMed ID: 19029838
[TBL] [Abstract][Full Text] [Related]
55. Low frequency of PIK3CA gene mutations in hepatocellular carcinoma in Chinese population.
Li X; Zhang Q; He W; Meng W; Yan J; Zhang L; Zhu X; Liu T; Li Y; Bai Z
Pathol Oncol Res; 2012 Jan; 18(1):57-60. PubMed ID: 21667306
[TBL] [Abstract][Full Text] [Related]
56. Screening for
Al-Qahtani WS; Alduwish MA; Al-Olayan EM; Aljarba NH; Em AH; Albani FG; Domiaty DM; Al-Otaibi AM; Qattan SMA; Almurshedi AS; Elasbali AM; Ahmed HG; Almutlaq BA
J Obstet Gynaecol; 2021 Oct; 41(7):1127-1133. PubMed ID: 33475035
[TBL] [Abstract][Full Text] [Related]
57. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.
Kim JH; Lee JS; Kim EJ; Park KH; Kim KH; Yi SY; Kim HS; Cho YJ; Shin KH; Ahn JB; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Noh SH; Rha SY; Kim HS
Oncotarget; 2016 Apr; 7(17):24549-58. PubMed ID: 27016421
[TBL] [Abstract][Full Text] [Related]
58. Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Kuroda T; Kohno T
Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380
[TBL] [Abstract][Full Text] [Related]
59. PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
Kato N; Sato Y; Kamataki A; Fukase M; Uchigasaki S; Kurose A
Hum Pathol; 2019 Apr; 86():32-37. PubMed ID: 30496799
[TBL] [Abstract][Full Text] [Related]
60. Molecular profiling of clear cell adenocarcinoma of the urinary tract.
Lin CY; Saleem A; Stehr H; Zehnder JL; Pinsky BA; Kunder CA
Virchows Arch; 2019 Dec; 475(6):727-734. PubMed ID: 31372739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
